Last edition
News about "Commercialise Injectable Semaglutide"
Lupin Partners with Galenicum to Commercialise Injectable Semaglutide
Global pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Galenicum Health, S.L.U. through its subsidiary, Lupin Atlantis Holdings SA (LAHSA), for finished injectable formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Commercialise Injectable Semaglutide | 21/01/2026 | By Darshana | 136
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members